Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study-Reference-Cited by-同舟云学术

Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study

Published:2013-02-08 Issue:1 Volume:6 Page:
ISSN:1756-8722
Container-title:Journal of Hematology & Oncology
language:en
Short-container-title:J Hematol Oncol

Author:

Liu Hui,Zhai Xiao,Song Zhaoyang,Sun Jing,Xiao Yang,Nie Danian,Zhang Yu,Huang Fen,Zhou Hongsheng,Fan Zhiping,Tu Sanfang,Li Yonghua,Guo Xutao,Yu Guopan,Liu Qifa

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Biology,Hematology

Link

http://link.springer.com/content/pdf/10.1186/1756-8722-6-15.pdf

Reference30 articles.

1. De Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C, Andersson BS, Gajewski J, Couriel D, Cortes J, Donato M, Neumann J, Champlin R, Giralt S: Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004, 104 (3): 865-872. 10.1182/blood-2003-11-3750.

2. Copelan EA: Hematopoietic stem-cell transplantation. N Engl J Med. 2006, 354 (17): 1813-1826. 10.1056/NEJMra052638.

3. Ali N, Adil SN, Shaikh MU, Moosajee M, Masood N: Outcome of match related allogeneic stem cell transplantation procedures performed from 2004 till 2011. Exp Hematol Oncol. 2012, 1 (1): 13-10.1186/2162-3619-1-13.

4. Ciurea SO, Andersson BS: Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Tr. 2009, 15 (5): 523-536. 10.1016/j.bbmt.2008.12.489.

5. Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C, Stewart D, Ruether JD, Morris D, Glick S, Gyonyor E, Andersson BS: Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Tr. 2002, 8 (9): 468-476. 10.1053/bbmt.2002.v8.pm12374451.

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Polymeric nanoparticles as delivery vehicles for targeted delivery of chemotherapy drug fludarabine to treat hematological cancers;Inorganic Chemistry Communications;2024-09

2. Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial;Blood Cancer Journal;2024-08-21

3. A network meta-analysis of the effectiveness of different basic preconditioning regiments in allogeneic hematopoietic stem cell transplantation;Hematology;2024-07-15

4. Haploidentical and Matched Sibling Transplantation for Acute Myeloid Leukemia: A Hospital-Based Study;Journal of Hematology;2023-12

5. Myeloablative Dose of Busulfan and Fludarabine Combined with In Vivo T Cell Depletion Is Safe and Effective Conditioning for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients;Transplantation and Cellular Therapy;2023-11